Myocarditis & mRNA Vaccines
A complete evidence review of the documented association between mRNA COVID-19 vaccines and myocarditis
Myocarditis (inflammation of the heart muscle) and pericarditis (inflammation of the lining around the heart) have been identified as rare but documented adverse events following mRNA COVID-19 vaccination. This page presents the evidence transparently — including incidence rates, risk factors, clinical course, and comparison to COVID-19-associated myocarditis.
This is a confirmed, established adverse event recognised by the CDC, FDA, WHO, and other major regulatory agencies worldwide.
Incidence Rates by Age, Sex, and Dose
Multiple studies and surveillance systems have documented the incidence of vaccine-associated myocarditis. The highest rates are observed in young males after the second dose.
| Age Group | Sex | Dose | Estimated Rate (per million doses) |
|---|---|---|---|
| 12–17 years | Male | 2nd dose | 70–105 |
| 18–24 years | Male | 2nd dose | 50–80 |
| 12–17 years | Female | 2nd dose | 8–12 |
| 18–24 years | Female | 2nd dose | 5–10 |
| 65+ years | Both | Any | 1–3 |
Source: CDC surveillance data, ACIP presentations (2021–2022). Rates may vary based on case definition, surveillance method, and time period. These are estimates — see sources for full methodology.
Clinical Course and Outcomes
- Onset timing: Symptoms typically begin within 7 days of vaccination (most commonly 2–4 days)
- Severity: Most cases are mild to moderate; severe cases are rare
- Hospitalization: Approximately 70–80% of identified cases were hospitalized, often for monitoring rather than critical care
- Recovery: Most patients recover with standard treatment; long-term follow-up data is still being collected
- Outcomes: Death is extremely rare; most patients have normal cardiac function at follow-up
Important note on detection: Enhanced surveillance (including active hospital-based monitoring) detects more cases than passive reporting alone. The true incidence may be higher than currently estimated due to mild or asymptomatic cases that go undetected.
Comparison to COVID-19-Associated Myocarditis
Research consistently shows that the risk of myocarditis from SARS-CoV-2 infection is higher than from vaccination:
- COVID-19 infection risk: Studies estimate myocarditis risk from infection is approximately 2–5 times higher than from vaccination (Patone et al., 2022)
- Infection-associated rates: Estimated at 40–150 per million infections in young males
- Severity comparison: Infection-associated myocarditis tends to be more severe on average
- This comparison should inform but not override individual clinical decisions — personal risk factors should be discussed with healthcare providers
Regulatory Responses
FDA (2021)
Added a warning about myocarditis/pericarditis to Emergency Use Authorizations for Pfizer-BioNTech and Moderna COVID-19 vaccines. Warning retained in full approval labelling.
CDC ACIP (2021)
Recommended updated guidance for clinicians and updated screening considerations. Noted that benefits of vaccination continue to outweigh risks while monitoring continues.
WHO (2022)
Noted that benefits of vaccination continue to outweigh risks across population groups, but advised continued monitoring and updated guidance for clinicians.
UK MHRA (2021)
Added myocarditis and pericarditis to the Product Information for mRNA vaccines with revised guidance for healthcare professionals.
Limitations and Ongoing Research
- Long-term cardiac outcomes are still being studied — most follow-up data is 3–12 months
- True incidence likely higher than reported due to underdiagnosis of mild cases
- Mechanistic understanding of why mRNA vaccines trigger myocarditis in some individuals is still under investigation
- Optimal dosing intervals and whether lower doses reduce risk is an active research area
- Data from updated COVID-19 vaccine formulations (XBB, JN.1 variants) is still accumulating
Sources & Citations
CDC. "Myocarditis and Pericarditis After COVID-19 Vaccination." Centers for Disease Control and Prevention. 2022.
https://www.cdc.gov/coronavirus/2019-ncov/vaccines/safety/myocarditis.htmlPatone M, et al. "Risks of myocarditis, pericarditis, and cardiac arrhythmias associated with COVID-19 vaccination or SARS-CoV-2 infection." Nature Medicine. 2022;28:410-422.
https://doi.org/10.1038/s41591-021-01630-0Witberg G, et al. "Myocarditis after Covid-19 Vaccination in a Large Health Care Organization." New England Journal of Medicine. 2021;385:2132-2139.
https://doi.org/10.1056/NEJMoa2110737Li R, et al. "Myocarditis and Other Cardiovascular Complications of the mRNA-Based COVID-19 Vaccines." Cureus. 2021;13(6):e15400.
https://doi.org/10.7759/cureus.15400FDA. "Comirnaty and Paxlovid: FDA-Approved Products." U.S. Food and Drug Administration.
https://www.fda.gov/emergency-preparedness-and-response/coronavirus-disease-2019-covid-19/comirnaty-and-paxlovid-fda-approved-products